NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 13 filers reported holding NUVECTIS PHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,067,428 | -15.5% | 168,630 | +9.4% | 0.08% | -12.6% |
| Q1 2024 | $1,263,866 | +6.7% | 154,130 | +8.5% | 0.10% | +2.2% |
| Q4 2023 | $1,184,614 | -21.0% | 142,040 | +22.0% | 0.09% | -27.9% |
| Q3 2023 | $1,500,138 | +4.3% | 116,380 | +29.2% | 0.13% | +9.3% |
| Q2 2023 | $1,438,274 | -23.7% | 90,061 | -37.4% | 0.12% | -28.0% |
| Q1 2023 | $1,885,218 | +88.6% | 143,800 | +7.9% | 0.16% | +80.2% |
| Q4 2022 | $999,750 | +6.0% | 133,300 | +0.2% | 0.09% | -30.0% |
| Q3 2022 | $943,000 | -30.4% | 133,000 | +9.9% | 0.13% | -26.1% |
| Q2 2022 | $1,355,000 | – | 121,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BALDWIN BROTHERS LLC/MA | 168,630 | $1,067,428 | 0.08% |
| FORBES J M & CO LLP | 47,419 | $300,162 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 48,339 | $306 | 0.02% |
| Point72 Asia (Singapore) Pte. Ltd. | 9,203 | $58,252 | 0.01% |
| BAXTER BROS INC | 12,500 | $79,125 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 23,173 | $146,685 | 0.01% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 19,170 | $121,346 | 0.00% |
| Renaissance Technologies | 74,500 | $471,585 | 0.00% |
| Centiva Capital, LP | 13,300 | $84,189 | 0.00% |
| Tower Research Capital LLC (TRC) | 5,996 | $37,955 | 0.00% |